Phase 2 N=40 Adjunctive Linezolid for the Treatment of Tuberculous Meningitis
Tuberculosis, Meningeal
Primary: Drug Clearance (CL/F) — 6.24 L/hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
Acute Respiratory Distress Syndrome · ARDS (Moderate or Severe) · COVID-19 Pneumonia
Primary: Incidence of Grade 3-5 Infusional Toxicities and Predefined Hemodynamic or Respiratory Adverse Events Related to the Infusion of MSC — 0; 0 Participants
Phase 2 N=52 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Primary: Safety and Tolerability — 10; 8; 2; 0 Participants
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
Phase 2 N=353 Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) of Confirmed Relapses — 0.205; 0.142; 0.150 Confirmed relapses per year
Phase 2 N=24 Olaparib in Treating Patients With Stage IV Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Objective Response Rate — 1; 15 Participants
Phase 2 N=233 A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
Sarcopenia · Gait Disorders in Old Age · Muscle Weakness
Primary: Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test — 0.0093; 0.0457; 0.0478; -0.2886 Meter/Second (m/s) — p=0.2437
Phase 2 N=197 ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
COVID-19 Disease
Primary: Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Index Virus Neutralizing Antibody Titers at 2 Weeks After the Last Vaccination — 516.7; 970.9; 978.9 titer
Phase 2 N=102 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Dyslipidemia · Hypercholesterolemia · High Cholesterol
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] — -0.78; -25.90; -33.78; -36.80 percent change from baseline — p=<.0001
Phase 2 N=488 Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acute Respiratory Distress Syndrome · Critical Illness · Respiratory Failure
Primary: Days Alive and Free of Organ Support to Day 28 — 20.2; 20.5; 19.7; 18.4 days — p=0.65
Phase 2 N=38 Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Primary: Proportion of Subjects With a Complete Response Rate (CR) at 1 Year of Therapy — 0.26 proportion of participants
Phase 2 N=76 Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
Small-cell Lung Cancer
Primary: Main Part: Objective Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Independent Review Committee (IRC) — 5.5…
Phase 2 N=256 Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Incontinence Episode Frequency (IEF) Per 24 Hours at Baseline and Week 8 — 2.9; 2.5; 2.6; 2.0 episodes
Phase 2 N=139 A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Diabetic Retinopathy
Primary: Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36…
Phase 2 N=128 Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years